Marksans Pharma Limited — Updates, 08-08-2025: Press Release

Marksans Pharma has received USFDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC) through its wholly owned subsidiary. This generic is bioequivalent to AstraZeneca's Prilosec, commonly used for heartburn. This significant business development opens access to the lucrative over-the-counter market in the US for a high-demand product. The approval diversifies Marksans' product portfolio and is expected to drive future revenue growth, providing a clear pathway for commercialization in a key therapeutic segment.